Timber Pharmaceuticals — Investor Presentation (September 2022)
29 slides from Timber Pharmaceuticals's investor presentation, Sep 12, 2022
Slide 1: Building Bridges in Medical Dermatology
Building Bridges in Medical Dermatology Investor Presentation September 2022 NYSE American: TMBR
Slide 2: Safe Harbor Statement
NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut
Slide 3: Timber Pharmaceuticals specialty pharmaceutical company for rare dermatologic diseases
NYSE American: TMBR 3 3 NYSE American: TMBR Timber Pharmaceuticals is a specialty pharmaceutical company devoted to transforming the lives of patients with rare, high impact dermatologic diseases by utilizing advanced translational science.
Slide 4: Business Model Focused on Orphan Drug Indications and the 505(b)(2) Pathway
NYSE American: TMBR Timber Business Model 4 Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Timber can be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires potentially smaller and less costly drug trials with greater fl
Slide 5: Investment Highlights
NYSE American: TMBR Investment Highlights 5 • Positioning to become a leading rare disease dermatology company with a focus on rare and orphan dermatologic diseases, led by a management team with a proven track record in development and commercialization • Lead product candidate TMB - 001 has achiev
Slide 6: Product/Indication Pipeline
Product/Indication TMB - 001 (topical isotretinoin) Congenital ichthyosis 1 TMB - 003 ( topical Sitaxsentan ) Sclerotic Skin Diseases 2 1 Indications under consideration include Darier’s Disease, Severe Acne and/or Sebaceous Hyperplasia 2 Initially to be investigated in Lichen Sclerosis; additional
Slide 7: Topical Isotretinoin: Moderate to Severe Congenital Ichthyosis (CI)
NYSE American: TMBR 7 7 NYSE American: TMBR TMB - 001 – Topical Isotretinoin Moderate to Severe Congenital Ichthyosis (CI)
Slide 8: Multiple FDA Milestones Received
NYSE American: TMBR 8 TMB - 001 has Received Multiple FDA Milestones May 2022 – FDA Breakthrough therapy status granted • A process designed to expedite the development and review of drugs that are intended to treat serious or life - threatening conditions April 2022 – FDA Fast Track designation
Slide 9: Unmet Need: Congenital Ichthyosis Quick Facts
NYSE American: TMBR Unmet Need: An efficacious and safe treatment that can be used long term to cover a large body surface area .. 9 Congenital Ichthyosis – Quick facts A rare disorder of keratinization affecting ~ 80,000 people in the U.S. and >1.5 million globally Prevalence • X - Linked Ichthyo
Slide 10: Topical Isotretinoin in CI
NYSE American: TMBR 10 TMB - 001 - Topical Isotretinoin in CI Patented topical formulation that minimizes systemic absorption, thereby allowing for chronic treatment Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is only available
Slide 11: Phase 2b Study Design
NYSE American: TMBR 11 TMB - 001 Phase 2b Study Design Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB - 001 for Treatment of Congenital Ichthyosis Primary Objective Proportion of subjects with Visual Index of Ichthyosis Severity (VIIS) treatment success, defined as 5
Slide 12: CONTROL Study - Efficacy Per Protocol
NYSE American: TMBR 12 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus
Slide 13: CONTROL Study - Efficacy Intent to Treat
NYSE American: TMBR 13 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the ITT Population in 0.05% dose achieved a 2 point reduction in IGA versus. 8% in the
Slide 14: CONTROL Study Lamellar Ichthyosis patient (responder)
NYSE American: TMBR 14 TMB - 001 CONTROL Study 21 year old patient with Lamellar Ichthyosis (ALOX12B) - 0.05% arm (responder) End Of Study – Visit 6 Baseline
Slide 15: CONTROL Study Lamellar Ichthyosis patient
NYSE American: TMBR 15 TMB - 001 CONTROL Study 39 year old patient with Lamellar Ichthyosis (0.05%) End Of Study – Visit 6 Baseline
Slide 16: Phase 3 ASCEND Study Design
NYSE American: TMBR 16 TMB - 001 Phase 3 Study Design Title The ASCEND Study: A Phase 3, Multicenter, Double Blind Vehicle Controlled Study of TMB - 001 with a parallel Optional Maximal Use Arm - in the treatment of RXLI or ARCI Ichthyosis in Subjects Aged > 6 Years Primary Objectives • To ascertain
Slide 17: TMB-003 Topical Sitaxsentan Sclerotic Skin Diseases
NYSE American: TMBR 17 17 NYSE American: TMBR TMB - 003 - Topical Sitaxsentan Sclerotic Skin Diseases
Slide 18: Topical Sitaxsentan for Sclerotic Skin Diseases
NYSE American: TMBR 18 TMB - 003 Topical Sitaxsentan for Sclerotic Skin Diseases Highly Selective ET - A inhibitor Sitaxsentan is a highly selective (6,500:1) ET - A receptor antagonist. • It was previously on the market in the E.U., Canada and Australia as an oral treatment for PAH but was volunt
Slide 19: Lichen Sclerosis
NYSE American: TMBR 19 Lichen Sclerosis Rare chronic disease of vulvae and perianal areas which affects approximately 160,000 women in the U.S.* Lichen Sclerosis affects both sexes, but is predominant in women • Prevalence 0.1 - 1.7% of women; diagnosed more by gynecologists than dermatologists •
Slide 20: Scleroderma
NYSE American: TMBR 20 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in
Slide 21: Multiple Barriers to Entry
NYSE American: TMBR Multiple Barriers to Entry 21 Orphan exclusivity granted for both strategic assets • 7 years in U.S., 10 years in E.U. and Japan Patents granted and pending globally Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidatio
Slide 22: World Class Clinical Advisors and Partners
NYSE American: TMBR World Class Clinical Advisors and Partners 22 • Amy S. Paller , MD Chair and Professor of Dermatology and Pediatrics, Northwestern University • Keith Choate, MD, PhD Professor of Dermatology, Pathology, and Genetics, Yale University • Joyce Teng, MD Professor and Director of Pedi
Slide 23: John Koconis, Chairman and CEO; Alan Mendelsohn, CMO
NYSE American: TMBR John Koconis, MBA, Chairman and CEO • Seasoned Pharmaceutical executive with over 25 years experience leading successful teams in global markets and having launche d multiple market leading products in Dermatology • President & CEO of LEO Pharma (U.S.), established a market leadi
Slide 24: Joseph Lucchese, CFO and Management
NYSE American: TMBR Joseph Lucchese, CFO • Chief Financial Officer of Timber Pharmaceuticals • Founding member and Managing Director of Oncology Partners; Managing Director at BlueStone Capital Partners, headed the Private Placement desk • Portfolio Manager and Chief Financial Officer of the MicroCa
Slide 25: Independent Board of Directors
NYSE American: TMBR Independent Board of Directors 25 Lead Independent Board Member Respected expert in SEC reporting and internal controls with extensive financial leadership experience as CFO at several public life sciences companies. Independent Board Member Professor of Dermatology at New York U
Slide 26: Key Takeaways
NYSE American: TMBR Key Takeaways 26 Rare, High Need Medical Dermatology Large Market Potential Multiple Shots on Goal De - Risked Portfolio Management Expertise • High unmet needs with large market potential • All strategic programs have been granted Orphan Drug status • No approved treatments for
Slide 27: Investor Contact Information
www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 NYSE American: TMBR
Slide 28: Appendix/Additional Slides
www.timberpharma.com APPENDIX/Additional Slides NYSE American: TMBR
Slide 29: Topical Isotretinoin in CI
NYSE American: TMBR 29 TMB - 001 Topical Isotretinoin in CI Baseline Day 57 Day 84 2 3 1 Vehicle TMB - 001 (0.1%) TMB - 001 (0.1%) TMB - 001 (0.1%) Percent of Subjects Achieving a 2 - point Reduction on Day 57 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% IGA Scaling Vehicle Active 0.1% Primary measure was
Timber Pharmaceuticals — Investor Presentation (September 2022) on 6ix